Abstract
Objective. Identification of clinical, laboratory, and instrumental factors more common in bacterial pneumonia compared to viral pneumonia, including COVID-19. Materials and Methods. This retrospective case-control study included hospitalized adults with communityacquired bacterial pneumonia and viral lung injury, including COVID-19. Patients were included taking into account age, gender, hospitalization department (general ward or ICU), and Charlson comorbidity index. Clinical, demographic, laboratory, and instrumental data on admission were studied. Unadjusted odds ratios (OR) were calculated using univariate logistic regression (for quantitative indicators) and contingency table analysis (for categorical indicators); adjusted OR were calculated using multivariate logistic regression. Results. The community-acquired bacterial pneumonia group included 100 patients, and the viral lung injury group included 300 patients. Among the causative agents of bacterial pneumonia, Streptococcus pneumoniae was the most common; in the group of viral lung injury, SARS-CoV-2 predominated. In multivariate analysis, the presence of chills (OR and 95% CI: 22.1 [6.8–72.6], p < 0.001), unilateral infiltration according to X-ray or computer tomography (OR and 95% CI: 17.9 [ 7.3–44.1], p < 0.001), altered level of consciousness (OR and 95% CI: 3.2 [1.2–8.5], p = 0.019), use of vasopressors in the first 24 hours of hospitalization ( OR and 95% CI: 11.8 [2.5–55.9], p = 0.002), higher heart rate (OR and 95% CI: 9.1 [2.2–38.6], p = 0.003) and neutrophil/lymphocyte index (OR and 95% CI: 1.4 [1.1–1.9], p = 0.021), as well as the absence of fatigue (OR and 95% CI: 0.2 [0.08–0.40], p < 0.001) and lower total protein (OR and 95% CI: 0.2 [0.02–1.00], p = 0.049) are more typical for bacterial pneumonia compared to viral lung injury. Conclusions. Differential diagnosis between community-acquired bacterial pneumonia and viral lung injury, including COVID-19, requires a comprehensive analysis of clinical, laboratory, and instrumental data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Clinical Microbiology and Antimicrobial Chemotherapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.